We feel now is a pretty good time to analyse REGENXBIO Inc.'s (NASDAQ:RGNX) business as it appears the company may be on the cusp of a considerable accomplishment. REGENXBIO Inc., a clinical-stage ...

H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $34 from $36 and keeps a Buy rating on the shares following the Q4 results. Published first on TheFly – the ultimate ...

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $22.00. The company’s shares closed yesterday at ...